EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ferozsons Laboratories's Enterprise Value is ₨23,397 Mil.
Ferozsons Laboratories's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₨-547 Mil. Therefore, Ferozsons Laboratories's EV-to-FCF for today is -42.77.
The historical rank and industry rank for Ferozsons Laboratories's EV-to-FCF or its related term are showing as below:
KAR:FEROZ'
s EV-to-FCF Range Over the Past 10 Years
Min: -7499.71 Med: -3.03 Max: 318.56
Current: -42.82
During the past 11 years, the highest EV-to-FCF of Ferozsons Laboratories was 318.56. The lowest was -7499.71. And the median was -3.03.
KAR:FEROZ's EV-to-FCF is ranked worse than 100% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.75
vs KAR:FEROZ: -42.82
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ferozsons Laboratories's PE Ratio (TTM) for today is calculated as:
Ferozsons Laboratories's share price for today is ₨411.15.
Ferozsons Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨21.660.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAR:FEROZ vs ZTS, UTHR, VTRS: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ferozsons Laboratories's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ferozsons Laboratories EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ferozsons Laboratories's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Ferozsons Laboratories's EV-to-FCF falls into.
Ferozsons Laboratories's current Enterprise Value is ₨23,397 Mil.
Ferozsons Laboratories's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₨-547 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ferozsons Laboratories (KAR:FEROZ) has a EV-to-FCF of -42.77 as of Jul. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ferozsons Laboratories and its competitors. According to the industry distribution chart, Ferozsons Laboratories ranks #999999 out of 564 companies in the Drug Manufacturers industry.
Is Ferozsons Laboratories' EV-to-FCF too high?
Ferozsons Laboratories' current EV-to-FCF is -42.77. Based on the distribution chart, Ferozsons Laboratories ranks #999999 out of 564 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ferozsons Laboratories has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ferozsons Laboratories' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ferozsons Laboratories ranks #999999 out of 564 companies for EV-to-FCF. This places Ferozsons Laboratories in the lower half of its industry. The industry median EV-to-FCF is 20.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.75, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ferozsons Laboratories and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ferozsons Laboratories's current EV-to-FCF is -42.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ferozsons Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ferozsons Laboratories (KAR:FEROZ) is currently considered Fairly Valued. The stock's GF Value™ is ₨418.18, compared to a current price of ₨411.15 — trading 1.7% below its estimated fair value. The current EV-to-FCF is -42.77. Ferozsons Laboratories' overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Ferozsons Laboratories (KAR:FEROZ), the current EV-to-FCF is -42.77 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ferozsons Laboratories (KAR:FEROZ) Overvalued in 2026?
Based on GuruFocus' analysis, Ferozsons Laboratories stock appears to be undervalued.
The current stock price of ₨411.15 is trading 1.7% below its estimated GF Value™ of ₨418.18.
GuruFocus considers Ferozsons Laboratories to be Fairly Valued.
Key valuation signals for KAR:FEROZ:
EV-to-FCF: -42.77
GF Value™: ₨418.18 vs. price of ₨411.15 (1.7% below fair value)
No single metric tells the full story. See the KAR:FEROZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ferozsons Laboratories Ltd is a pharmaceutical company. It is engaged in the import, manufacture, and sale of pharmaceuticals products and medical devices. The company operates in the therapeutic areas of dermatology, anti-infective treatments, gastroenterology, hepatology, cardiology, and diabetes. It manufactures tablets, capsules, syrups, suspensions, creams, and ointments. The company operates in three segments namely Ferozsons, BF Biosciences, and Others. The group sells its products in Pakistan and internationally, of which the majority of the revenue is generated from the sales made in Pakistan.
76GF Score
Get the complete analysis for KAR:FEROZ
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:FEROZ has been successfully added to your 
